Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment

    188356_67900_Estimated_dose_exposure_of_the_neonate.pdf (136.8Kb)
    Access Status
    Open access
    Authors
    Ilett, K.
    Hackett, L.
    Gower, Shelley
    Doherty, D.
    Hamilton, D.
    Bartu, Anne
    Date
    2012
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Ilett, Kenneth F. and Hackett, L. Peter and Gower, Shelley and Doherty, Dorata A. and Hamilton, Dale and Bartu, Anne E. 2012. Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. Breastfeeding Medicine. 7 (4): pp. 269-274.
    Source Title
    Breastfeeding Medicine
    DOI
    10.1089/bfm.2011.0096
    ISSN
    1556-8342
    Remarks

    This is a copy of an article published in the Journal Breastfeeding Medicine. © 2011 copyright Mary Ann Liebert, Inc.; Breastfeeding Medicine Journal is available online at: http://online.liebertpub.com

    URI
    http://hdl.handle.net/20.500.11937/6542
    Collection
    • Curtin Research Publications
    Abstract

    Objective: The aim of the present study was to estimate the dose of buprenorphine and its primary metabolite norbuprenorphine that a breastfed infant would receive during maternal maintenance treatment with buprenorphine. Study Design: Seven pregnant opioid-dependent women taking buprenorphine (median, 7mg/day; range, 2.4–24 mg) and who intended to breastfeed were recruited. After lactation was established, several milk samples were collected from each subject over a 24-hour dose interval, and buprenorphine and norbuprenorphine concentrations were measured by liquid chromatography–tandem mass spectrometry. The average concentration (Cavg) across the dose interval was estimated as for both buprenorphine and norbuprenorphine (as buprenorphine equivalents). Absolute infant dose (AID), defined as Cavg daily milk intake, and relative infant dose (RID), defined as 100 AID/weight-adjusted maternal daily dose, via milk were calculated, assuming a milk intake of 0.15 L/kg/day. The infant’s health and progress were assessed directly and by questionnaire on the study day. Results: Mean (95% confidence interval) norbuprenorphine concentration in milk and AID values (1.94 [0.79–3.08] μg/L and 0.29 [0.12–0.46] μg/kg/day, respectively) were approximately half those for buprenorphine (3.65[1.61–5.7] μg/L and 0.55 [0.24–0.85] μg/kg/day, respectively). Similarly, the mean RID values were 0.18% (0.11–0.25%) for norbuprenorphine and 0.38% (0.23–0.53%) for buprenorphine. The breastfed infants showed no adverse effects, were all in good health, and were progressing as expected. Conclusion: Thus the dose of buprenorphine and norbuprenorphine received via milk is unlikely to cause any acute adverse effects in the breastfed infant.

    Related items

    Showing items related by title, author, creator and subject.

    • The wellbeing of infants exposed to Buprenorphine via breast milk at 4 weeks of age
      Gower, Shelley; Bartu, Anne; Ilett, K.; Doherty, D.; McLaurin, R.; Hamilton, D. (2014)
      Background: Buprenorphine has been available in Australia since 2000 as an alternative pharmacotherapy to methadone for the treatment of opioid dependence. However, there is little information in the literature regarding ...
    • Buprenorphine exposure in infants of opioid-dependent mothers at birth
      Bartu, Anne; Ilett, K.; Hackett, L.; Doherty, D.; Hamilton, D. (2012)
      Background: Buprenorphine, a partial opioid agonist used in treating opioid dependence, is not approved in Australia for use in pregnancy. Nevertheless, many pregnant women choose to remain on the drug. Aim: To investigate ...
    • Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk
      Salman, S.; Sy, S.; Ilett, K.; Page-Sharp, Madhu; Paech, M. (2011)
      Purpose: The aim of this investigation was to demonstrate that nonlinear mixed-effects population pharmacokinetic (PK) modeling can be used to evaluate data from studies of drug transport/excretion into human milk and ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.